Correct Answer: A. Aspirin+heparin
Antiphospholipid syndrome (APS) in pregnancy is a thrombophilic state that causes recurrent pregnancy loss through placental infarction and thrombosis. The pathophysiology involves antiphospholipid antibodies (anticardiolipin, anti-β2 glycoprotein-I, lupus anticoagulant) triggering a hypercoagulable state and complement activation, leading to placental insufficiency and fetal loss, typically in the second and third trimesters.
The gold standard treatment for APS in pregnancy is low-dose aspirin (75–100 mg daily) combined with prophylactic low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). Aspirin provides antiplatelet effect and reduces thrombosis risk, while heparin offers anticoagulation and has immunomodulatory properties (reduces complement activation and improves placental perfusion). This dual approach significantly improves live birth rates from ~30% to >70% in APS pregnancies. Heparin is preferred over warfarin in pregnancy because warfarin is teratogenic (fetal warfarin syndrome), whereas heparin does not cross the placenta. According to Indian guidelines and international consensus (RCOG, ACOG), this combination is the standard of care for APS with recurrent pregnancy loss. Steroids are not first-line and are reserved for additional autoimmune complications (e.g., SLE overlap).
Why the other options are wrong
B. Aspirin+heparin+steroids — While steroids may be used in APS patients with concurrent SLE or severe thrombocytopenia, they are NOT standard first-line therapy for uncomplicated APS in pregnancy. Adding steroids increases maternal infection risk, gestational diabetes, and osteoporosis without proven additional benefit for live birth rates in isolated APS. This is an over-treatment trap—NBE tests whether students know that dual therapy (aspirin+heparin) is sufficient. C. Aspirin only — Aspirin monotherapy is inadequate for APS in pregnancy with recurrent losses. While aspirin reduces thrombotic risk, it lacks the anticoagulant potency needed to prevent placental thrombosis in this hypercoagulable state. Studies show aspirin alone has poor outcomes (~50% live birth rate); heparin addition is mandatory. This option tests whether students confuse APS thromboprophylaxis with primary prevention in low-risk pregnancies. D. Aspirin+steroids — This combination omits heparin, the critical anticoagulant component. Steroids alone do not provide anticoagulation and cannot replace heparin's role in preventing placental thrombosis. This is a distractor that may appeal to students who incorrectly think APS is primarily an inflammatory condition requiring immunosuppression rather than a thrombophilic disorder requiring anticoagulation.
High-Yield Facts
- APS in pregnancy causes recurrent fetal loss via placental thrombosis and infarction, not autoimmune rejection.
- Gold standard treatment: low-dose aspirin (75–100 mg/day) + LMWH/UFH throughout pregnancy and 6 weeks postpartum.
- Heparin is preferred over warfarin in pregnancy because it does not cross the placenta and avoids fetal warfarin syndrome.
- Live birth rate improves from ~30% to >70% with aspirin+heparin dual therapy in APS pregnancies.
- Steroids are NOT first-line in uncomplicated APS; reserved for SLE overlap or thrombocytopenia.
- Diagnosis criteria: clinical (recurrent pregnancy loss or thrombosis) + laboratory (anticardiolipin, anti-β2GP1, or lupus anticoagulant on ≥2 occasions >12 weeks apart).
Mnemonics
APS Pregnancy Treatment: HASTE Heparin + Aspirin = Standard Therapy for Early/recurrent loss in APS. Use this when you see 'recurrent abortion + APS' in any question. Why NOT steroids in APS? No Inflammation = No Steroids. APS is thrombophilic (clotting disorder), not inflammatory. Steroids add risk without benefit unless SLE is present.
NBE Trap
NBE pairs APS with "recurrent abortion" to test whether students confuse it with autoimmune/inflammatory causes (which would warrant steroids). The trap is thinking APS requires immunosuppression; it is fundamentally a thrombophilic disorder requiring anticoagulation, not immunosuppression.
Clinical Pearl
In Indian obstetric practice, APS is increasingly recognized in women with recurrent second/third-trimester losses and thrombotic events. Early diagnosis (via anticardiolipin/lupus anticoagulant testing) and prompt dual therapy with aspirin+LMWH from the first trimester dramatically improves outcomes—many Indian tertiary centers now screen high-risk recurrent abortion cases for APS to prevent unnecessary D&C procedures and enable successful pregnancies.
_Reference: DC Dutta's Textbook of Obstetrics (7th ed.), Ch. 8 (Antiphospholipid Syndrome in Pregnancy); Harrison's Principles of Internal Medicine, Ch. 139 (Antiphospholipid Syndrome)_